Evidence map›Paper›PMID 41993617›Full record

ReviewTheranostics2026

Cell-drug conjugates: a novel drug delivery system for cancer therapy.

Xiaoli Cheng, Mengyuan He, Yuanye Zeng, Aixue Li, Lianghao Yuan, Yongwei Gu, Haiqiang Jiang, Jiyong Liu

Abstract readReview
In one paragraph

Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaoli ChengSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Mengyuan HeSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Yuanye ZengDepartment of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Aixue LiDepartment of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Lianghao YuanCollege of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Yongwei GuDepartment of Pharmacy, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Haiqiang JiangSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Jiyong LiuSchool of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell-drug conjugates (CDCs) represent an advanced drug delivery platform that combines living cells with therapeutics, leveraging the biological properties of cells to achieve precise targeting. By conjugating drugs onto cell surfaces, CDCs preserve cell viability and achieve functional collaborative therapy between the therapeutics and living cells. Furthermore, the pharmacokinetics of drugs can be improved by leveraging many inherent functions of cells. This review systematically introduces the construction of CDCs as drug delivery systems, including carrier cells, coupling components, and conjugation strategies

Indexed as

Antineoplastic AgentsDrug CarriersDrug Delivery SystemsNeoplasmsAnimalsClinical Trials as TopicHumansAntineoplastic AgentsDrug Carrierscancer therapycell-drug conjugatesclinical translationdrug deliveryprecise targeting

Identifiers

PMID41993617
PMCPMC13080617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.